Log In Sign up
The largest database of trusted experimental protocols
> Procedures > Therapeutic or Preventive Procedure > Platelet Transfusion

Platelet Transfusion

Platelet Transfusion is the process of transferring platelet-rich blood components from a donor to a recipient.
Platelets play a crucial role in blood clotting and wound healing, making platelet transfusions essential for treating conditions like thrombocytopenia, cancer, and bleeding disorders.
This MeSH term describes the indications, methods, and considerations surrounding platelet transfusion procedures, as well as the potential risks and benefits.
Reasearchers can leverage PubCompare.ai's AI-powered platform to optimize their platelet transfusion protocols, locate the latest literature and patents, and identify the most reproducible and accurtae approaches.

Most cited protocols related to «Platelet Transfusion»

1
Defining Hematopoietic Engraftment Criteria
Neutrophil engraftment was defined as achieving an ANC of 0.5 × 109/L or greater for three consecutive days, and platelet recovery was defined as achieving a platelet count of 20 × 109/L or greater, without platelet transfusions, for seven days. A Hb level of at least 80 g/L without transfusion support is the accepted threshold for red cell engraftment [12 (link)]. Full donor chimerism was defined as ≥95 % leukocytes of donor origin in peripheral blood or marrow samples, measured according to our previous report. [14 (link)] Mixed chimerism was defined as more than 5 % but less than 95 % leukocytes of donor origin.
Primary GF included GR and PGF. As described in the introduction, GR is the failure to engraft neutrophils (ANC ≤0.5 × 109/L) by day +28 for three consecutive days and the absence of donor hematopoiesis. Because delayed red cell engraftment may happen for many months post-transplant and is more difficult to evaluate in an unarguable manner, in the present study, primary PGF was defined as the presence of three cytopenic counts (ANC ≤0.5 × 109/L, platelet ≤20 × 109/L, or hemoglobin (Hb) ≤80 g/L) beyond day +28 with a transfusion requirement associated with hypoplastic-aplastic BM, in the presence of complete donor chimerism. The patients with evidence of severe GVHD or hematologic relapse were excluded [14 (link)].
The diagnosis and grading of acute and chronic GVHD was assigned by the transplant center using standard criteria [42 (link), 43 (link)]. Transplant-related mortality (TRM), relapse, DFS, and overall survival (OS) was defined according to our previous studies [2 (link), 32 (link), 34 (link)].
Chang Y.J., Zhao X.Y., Xu L.P., Zhang X.H., Wang Y., Han W., Chen H., Wang F.R., Mo X.D., Zhang Y.Y., Huo M.R., Zhao X.S., Y K., Liu K.Y, & Huang X.J. (2015). Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets. Journal of Hematology & Oncology, 8, 84.
Publication 2015
BLOOD Blood Platelets Blood Transfusion Chimerism Diagnosis Donors Erythrocytes Grafts Hematopoiesis Hemoglobin A hemoglobin L hypoplasia Leukocytes Marrow Neutrophil Patients Platelet Counts, Blood Platelet Transfusion Relapse
2
Generation of Pdpn and Clec-2 Conditional Mice
To generate mice with loxP-flanked Pdpn alleles (Pdpnf/f), a targeting vector was constructed in which exon 2, the major coding exon of Pdpn gene, was flanked by loxP sites (Pdpnf/f), and the neomycin resistance selection cassette (Neo) was flanked by Frt sites (Supplementary Fig. 2a). The Not I-linearized construct was electroporated into C57BL/6-derived embryonic stem (ES) cells, and correctly targeted clones were identified by Southern blots. The Frt-flanked Neo was removed by transient expression of Flp recombinase in the positive ES clones to avoid potential undesirable effects of the Neo cassette. ES cells with normal karyotype bearing a floxed Pdpn allele were microinjected into B6/Tyr blastocytes, which were subsequently implanted into pseudopregnant foster mothers. Male chimaeras were bred with C57BL/6J females for germline transmission. Heterozygous mice were then crossed to generate Pdpnf/f mice (Supplemental Fig. 2a-b).
To generate mice with inducible deletion of PDPN (Pdpnf/f;CagCre), Pdpnf/f mice were crossed with the CAG-Cre-ERT2 Tg mice (B6.Cg-Tg(CAG-cre/Esr1*)5Amc/J, Jackson Laboratories)29 (link). To induce postnatal deletion of PDPN, tamoxifen (TM, MP Biomedical) was dissolved in ethanol/sunflower oil (1:9) and administered orally (p.o.) (20 μg per day) to pups from postnatal day (P) 1-5. Adult deletion was accomplished by administering TM p.o. (1 mg per day) for 5 consecutive days beginning at P21, then once a week thereafter. Wild-type littermates (WT, Pdpnf/w;CagCre or Pdpnf/f) treated with the same regimen were used as controls. Mice deficient for PDPN in pericytes/fibroblasts including FRCs (Pdpnf/f;PdgfrbCre) or in endothelial cells (Pdpnf/f;Tie2Cre) were generated by crossing Pdpnf/f mice with PdgfrbCre Tg mice [Tg(Pdgfrb-cre)9Rha]30 (link) or Tie2Cre Tg mice [Tg(Tek-cre)1Ywa]31 (link), respectively.
CLEC-2 conditional mice were generated in which exons 3 and 4 of the Clec-2 allele are flanked by loxP sites (Clec-2f/f). Deletion of exons 3 and 4 induces a premature stop codon that blocks the expression of CLEC-2’s extracellular domain (Supplementary Fig. 8a). ES clones with correct homologous recombination were microinjected into B6 blastocytes, which were subsequently implanted into pseudopregnant foster mothers. Male chimaeras were bred with ACTB-FLP1 females (B6.Cg-Tg(ACTFLPe)9205Dym/J, Jackson Laboratory) for germline transmission and removal of the Neo cassette. Heterozygous mice were then crossed to generate Clec-2f/f mice. Clec-2f/f mice were crossed with Pf4Cre Tg mice (C57BL/6-Tg(Pf4-cre)Q3Rsko/J, Jackson Laboratory) to generate mice deficient for CLEC-2 on platelets (Clec-2f/f;Pf4Cre mice).
Clec-2−/−9, Rag1−/− (Jackson Laboratories)32 (link), and S1Pless mice13 (link) were previously described. Mice were housed in specific pathogen–free barrier facilities. All mice were of mixed genetic background (129S and C57BL/6J) unless otherwise stated. Sex- and age-matched WT littermate controls were used for all experiments. Mice were included in studies if they exhibited more than 75% for PDPN deficiency and 95% for CLEC-2 deficiency. Random assignment to treatment groups was used in antibody blocking and platelet transfusion studies in vivo. No blinding was used in this study. Animal studies were approved by the Institutional Animal Care and Use Committee of the Oklahoma Medical Research Foundation.
Herzog B.H., Fu J., Wilson S.J., Hess P.R., Sen A., McDaniel J.M., Pan Y., Sheng M., Yago T., Silasi-Mansat R., McGee S., May F., Nieswandt B., Morris A.J., Lupu F., Coughlin S.R., McEver R.P., Chen H., Kahn M.L, & Xia L. (2013). Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2. Nature, 502(7469), 105-109.
Publication 2013
Adult Alleles Animals Blastocytes Blood Platelets Blot, Southern Clone Cells Cloning Vectors Codon, Nonsense Deletion Mutation Embryo Embryonic Stem Cells Endothelial Cells Ethanol Exons Females Fibroblasts FLP recombinase Genetic Background Germ Line Heterozygote Homologous Recombination Immunoglobulins Institutional Animal Care and Use Committees Karyotyping Males Mice, Laboratory mitogen-activated protein kinase 3, human Mothers Neomycin Oil, Sunflower Pericytes Platelet Transfusion RAG-1 Gene Specific Pathogen Free Stem, Plant Tamoxifen Transients Transmission, Communicable Disease Treatment Protocols
3
Eltrombopag for Myelodysplastic Syndromes
The primary end points were defined according to hematologic responses and toxic effects at 12 weeks. A platelet response was defined as an increase of 20,000 cells per cubic millimeter or more above the baseline value, or independence from platelet transfusions for a minimum of 8 weeks in patients who were previously transfusion-dependent. An erythroid response in patients with a pretreatment hemoglobin level of less than 9 g per deciliter was defined as an increase in the hemoglobin level by 1.5 g per deciliter or more without transfusion of packed red cells or a reduction in the number of units of packed red cells transfused by at least 4 units for 8 consecutive weeks, as compared with transfusion requirements during the 8 weeks preceding study entry. A neutrophil response was defined as an absolute increase in the neutrophil count of more than 500 per cubic millimeter; in patients with a pretreatment count of less than 500 per cubic millimeter, a response was defined as an increase of more than 500 per cubic millimeter or at least a 100% increase over the baseline neutrophil count.
Patients who met response criteria for one or more lineages at 12 weeks were deemed to have had a response. Patients who met criteria for a response at 12 weeks continued to receive eltrombopag for an additional 4 weeks to ensure the stability of the response and then could continue to receive eltrombopag for as long as the response was maintained. Hematologic responses in additional lineages were assessed in patients who had a response and who participated in the extension study. Toxic effects were measured with the use of the National Cancer Institute Common Terminology Criteria for Adverse Events (version 3) (http://ctep.cancer.gov/reporting/ctc.html).
Secondary end points were changes in blood counts measured as continuous variables, plasma thrombopoietin levels, and bone marrow cellularity; morphologic characteristics; metaphase cytogenetic profile; and reticulin fibrosis. Reticulin was graded according to standard guidelines.14 (link) Plasma cytokine levels, telomere length, and the immunophenotype of peripheral-blood cells were measured as described previously.2 (link),15 (link),16 (link)
Olnes M.J., Scheinberg P., Calvo K.R., Desmond R., Tang Y., Dumitriu B., Parikh A.R., Soto S., Biancotto A., Feng X., Lozier J., Wu C.O., Young N.S, & Dunbar C.E. (2012). Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia. The New England journal of medicine, 367(1), 11-19.
Publication 2012
BLOOD Blood Cells Blood Platelets Blood Transfusion Bone Marrow Cells Cells Cuboid Bone Cytokine eltrombopag Erythrocytes Fibrosis Hemoglobin Hemoglobin A Immunophenotyping Malignant Neoplasms Metaphase Neutrophil Patients Plasma Platelet Transfusion Red Blood Cell Transfusion Reticulin Telomere Thrombopoietin
4
Trilaciclib in second-/third-line ES-SCLC
This was a global, multicenter, phase Ib/IIa study (NCT02514447) of trilaciclib administered prior to topotecan for patients with ES-SCLC being treated in a second-/third-line setting. Data from the phase II portion of the study are presented.
Eligible patients were aged ≥ 18 years, with a confirmed diagnosis of ES-SCLC. Patients must have had disease progression during or after first- or second-line chemotherapy and been eligible to receive topotecan. Additional inclusion criteria (Supplementary Methods) included ≥ 1 measurable target lesion per Response Evaluable Criteria in Solid Tumors Version 1.1 (RECIST v1.1), adequate organ function, and Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 2. Patients were excluded if they had a history of topotecan treatment for SCLC or brain metastases requiring immediate treatment.
The study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Council for Harmonisation. The protocol and all study-related materials were approved by the institutional review board or independent ethics committee of each participating center. All patients provided written informed consent.
Patients were randomized to receive trilaciclib or placebo by an interactive web response system according to a randomization schedule generated by an unblinded statistician (Supplementary Methods). Randomization was stratified based on ECOG PS (0/1 versus 2) and sensitivity to first-line treatment, as defined by the investigator (sensitive versus resistant, whereby sensitivity was defined as having a complete response, partial response or stable disease with first-line treatment, and a progression-free interval ≥ 90 days after completion of first-line treatment; resistance was defined as a best response of progressive disease or a progression-free interval < 90 days). The sponsor, patients, investigators, and other staff were blinded to the treatment arm.
All patients received trilaciclib 240 mg/m2 or placebo administered as a 30-min IV infusion ≤ 4 h prior to topotecan 1.5 mg/m2 on each day that chemotherapy was administered. Treatment was administered on days 1–5 of each 21-day cycle. Patients were treated until progression, unacceptable toxicity, withdrawal of consent, or discontinuation by the patient or investigator. No dose modifications of trilaciclib were allowed. Topotecan dose reductions were only allowed twice for any patient and were permanent. To ensure an unconfounded assessment of trilaciclib’s ability to prevent CIM, administration of erythropoiesis-stimulating agents (ESAs) and primary prophylaxis with granulocyte colony-stimulating factors (G-CSFs) was prohibited in cycle 1, although therapeutic G-CSF was allowed in all cycles. As the risk of febrile neutropenia (FN) is predicted to be > 20% with topotecan, primary prophylaxis with G-CSF during cycle 1 would be indicated per standard guidelines. However, the safety monitoring committee agreed that for this study, prohibiting primary prophylaxis with G-CSF was permissible as long as the risk to patients receiving placebo was minimized by implementing a 2:1 (trilaciclib: placebo) randomization ratio, allowing the therapeutic use of G-CSF in cycle 1 and allowing investigators to only enroll those patients whose safety (as assessed by the treating physician) was not substantially compromised by this approach. Following completion of cycle 1, supportive care measures, including ESAs and G-CSF, were permitted per American Society of Clinical Oncology guidelines [19 (link)] and current prescribing information. Red blood cell (RBC) and platelet transfusions were allowed per investigator discretion throughout the entire treatment period.
Hart L.L., Ferrarotto R., Andric Z.G., Beck J.T., Subramanian J., Radosavljevic D.Z., Zaric B., Hanna W.T., Aljumaily R., Owonikoko T.K., Verhoeven D., Xiao J., Morris S.R., Antal J.M, & Hussein M.A. (2020). Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study. Advances in Therapy, 38(1), 350-365.
Publication 2020
Brain Metastases Diagnosis Disease Progression Drug Tapering Erythrocytes Erythropoiesis Stimulating Agents Ethics Committees Ethics Committees, Research Febrile Neutropenia Granulocyte Colony-Stimulating Factor Hypersensitivity Intravenous Infusion Neoplasms Patients Pharmacotherapy Physicians Placebos Platelet Transfusion Primary Prevention Safety Small Cell Lung Carcinoma Therapeutic Uses Topotecan trilaciclib Vitelliform Macular Dystrophy
5
Pediatric Platelet Transfusion Point Prevalence
This point prevalence study was an exploratory, international, prospective, cross-sectional design. Pediatric intensive care units were recruited through the Pediatric Critical Care Blood Research Network (BloodNet), Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) network, several international critical care societies, and sites who previously participated in an epidemiologic study of plasma transfusions (PlasmaTV).3 (link) Sites were encouraged to recruit across all pediatric critical care areas, including specialized pediatric cardiac critical care units, but were not required to do so. Each site was assigned six random weeks (between September 2016 to April 2017) and screened all seven days of each week. A child was considered eligible if admitted to the pediatric intensive care unit (PICU) during one of the screening days and between 3 days and 16 years old. A potential subject was enrolled if he/she received a platelet transfusion prescribed by the intensive care team during one of the screening days. Patients were excluded if life expectancy was less than 24 hours, gestational age was less than 37 weeks, or the patient was previously enrolled. The study was approved by the Institutional Review Board at each site, except for the UK where it was approved by the Health Research Authority of the National Health Service. Waiver of consent was granted at all sites except one in Italy that required written consent. Sites in Switzerland required a description of the study to be posted with an opt-out possibility for families.
Nellis M.E., Karam O., Mauer E., Cushing M.M., Davis P.J., Steiner M.E., Tucci M., Stanworth S.J, & Spinella P.C. (2018). Platelet Transfusion Practices in Critically Ill Children. Critical care medicine, 46(8), 1309-1317.
Publication 2018
Acute Lung Injury BLOOD Blood Transfusion Child Critical Care Ethics Committees, Research Gestational Age Heart Intensive Care Patients Plasma Platelet Transfusion Septicemia

Most recents protocols related to «Platelet Transfusion»

1
Pulmonary Endarterectomy Under Deep Hypothermia
PEA was performed from median sternotomy, the patient was cooled to 18°C to 20°C using cardiopulmonary bypass (CBP), and bilateral PEA was performed under deep hypothermic circulatory arrest. Unfractionated heparin (Leo Pharmaceutical Products, Denmark) was used for intraoperative anticoagulation monitored by activated clotting time (ACT) (target > 480 s Kaolin-ACT, Medtronic.Inc. ACTII, Minneapolis, MN, USA). Before the initiation of CBP, 500 to 1000 ml of blood was harvested, and returned to the patient after weaning off CPB, heparin reversal by protamine sulfate, and decannulation. During CPB to maintain patients’ volume status and to minimize the use of crystalloids (plasmalyte 50 mg/ml, Baxter) and possible volume overload autologous blood transfusion (cell saver), allogenic red blood cell (RBC) transfusions (Hb < 60 g/l), 2 to 6 units of solvent-detergent treated standardized plasma (Octaplas®, Octapharma AG, Lachen, Switzerland) or albumin 20% were used. Tranexamic acid was used 30 mg/kg intravenously before the surgical incision and again 15 mg/kg every 2 h for the duration of CPB. ACT was controlled every 20 min on CPB and 3 min after each heparin bolus. After CPB, administration of protamine and harvested blood infusion, coagulation status was controlled (heparinase-ACT, complete blood count, APTT, PT, fibrinogen, AT and D-dimer). Postoperatively in the operation room allogenic RBC were transfused if Hb < 90 g/l or Hct < 30%. The threshold for platelet transfusion was the platelet count <100 ×109/l and for standardized plasma, Octaplas®, PT < 30%.
Myllylahti L., Ropponen J., Lax M., Lassila R, & Nykänen A.I. (2023). Upregulation of Coagulation Factor VIII and Fibrinogen After Pulmonary Endarterectomy in Patients with Chronic Thromboembolic Pulmonary Hypertension. Clinical and Applied Thrombosis/Hemostasis, 29, 10760296231158369.
Publication 2023
Activated Partial Thromboplastin Time Albumins BLOOD Blood Transfusion, Autologous Cardiopulmonary Bypass Cells Circulatory Arrest, Deep Hypothermia Induced Complete Blood Count Detergents Erythrocytes fibrin fragment D Fibrinogen Heparin Heparin Lyase Kaolin Median Sternotomy Patients Pharmaceutical Preparations Plasma Plasmalyte A Platelet Counts, Blood Platelet Transfusion Protamines Red Blood Cell Transfusion Solutions, Crystalloid Solvents Sulfate, Protamine Surgical Wound Tranexamic Acid
2
Remission Criteria in Hematological Malignancies
Complete remission (CR) was defined as the morphological recovery evidenced by less than 5% blasts according to bone marrow biopsy with complete hematological recovery. CR with incomplete count recovery (CRi) was defined as the morphological recovery evidenced by less than 5% blasts according to bone marrow biopsy, but with absolute neutrophil count (ANC) ≤ 1,000/µL or platelets ≤ 100,000/µL. ORR was comprised of CR and CRi. Morphological leukemia-free state (MLFS) was defined as morphological recovery without hematological recovery (ANC ≤ 1,000/µL and platelets ≤ 100,000/µL) [14 (link)]. Transfusion independence was defined as any 8-week period where the patient did not require blood or platelet transfusions. Clinical benefit was characterized by achievement of response (CR, CRi, or MLFS) or transfusion independence.
Freeman T., Williams K., Puto M., Waller A., McLaughlin E.M., Blachly J.S, & Roddy J. (2023). Real-World Experience of Adults With Acute Myeloid Leukemia on Hypomethylating Agents With or Without Venetoclax at a Comprehensive Cancer Center. World Journal of Oncology, 14(1), 40-50.
Publication 2023
Biopsy Blood Blood Platelets Blood Transfusion Bone Marrow Leukemia Neutrophil Patients Platelet Transfusion
3
Filgrastim Biosimilar for PBSC Harvest
The primary outcome was to achieve successful harvest, defined as collection a minimum of 2×106/kg CD34+ cells. Secondary outcomes were time in days to achieve neutrophil and platelet engraftment. Neutrophil engraftment was considered complete when the absolute neutrophil count (ANC) was equal to or greater than 0.5×109/L for 3 consecutive days after infusion of PBSCs, whereas platelet engraftment was considered complete when the platelet count was 20×109/L or more for 7 consecutive days without platelet transfusion. We compared the safety of filgrastim (Zarzio®) versus Neupogen® in terms of allergic reaction and pain, number of leukapheresis sessions, and we compared the rescue use of plerixafor in both groups and the impact of biosimilar filgrastim (Zarzio®) in terms of cost savings.
Islami M.M., Khan M.A., Aseeri M.A., Alshamrani M.A., Alnatsheh A., Alamoudi S, & Alzahrani A.A. (2023). Comparison of Biosimilar Filgrastim with Innovator Fligrastim for Peripheral Blood Stem Cells Mobilization, Collection of CD34+ Stem Cells, and Engraftment in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation: A Single-Center Experience. Annals of Transplantation, 28, e938585-1-e938585-6.
Publication 2023
Allergic Reaction Biosimilars Blood Platelets Cells Filgrastim Leukapheresis Neupogen Neutrophil Pain Platelet Counts, Blood Platelet Transfusion plerixafor Safety
4
Predicting Hematological Complications Post-HSCT
PGF was defined as persistent neutropenia (absolute neutrophil count <0.5 × 109/L), thrombocytopenia (platelets <20 × 109/L), and/or hemoglobin <70 g/L for at least 3 consecutive days by day 28 post-HSCT with transfusion requirement in the presence of complete donor chimerism without disease relapse (15 (link), 16 (link)). SFPR was defined as platelets <20 × 109/L for 7 consecutive days or requirement of transfusion following reaching platelets ≥50 × 109/L without transfusion for 7 days post-HSCT (17 (link)). Meanwhile, the promotion of platelet engraftment was proposed to facilitate platelets ≥20 × 109/L without transfusion for 7 days post-HSCT. The number of megakaryocytes in bone marrow (BM) smear less than 7 in 1.5 cm × 3.5 cm area was considered as inadequate megakaryocyte status (18 (link), 19 (link)).
Ruan Y., Cao W., Luo T., Liu X., Liu Q., Xiao Y., Wu C., Xie D., Ren Y., Wu X, & Feng X. (2023). Avatrombopag for the treatment of thrombocytopenia in children's patients following allogeneic hematopoietic stem-cell transplantation: A pilot study. Frontiers in Pediatrics, 11, 1099372.
Publication 2023
Blood Platelets Blood Transfusion Bone Marrow Chimerism Donors Hemoglobin Leukopenia Megakaryocytes Neutrophil Platelet Transfusion Relapse Thrombocytopenia
5
Intraoperative Transfusion and Outcomes in Liver Transplantation
The data were retrieved from electronic health records of the patients via the hospital’s data system. The study’s primary outcome was intraoperative transfusion requirements of blood products. The secondary outcomes were ICU length of stay, postoperative time to extubate, incidence of postoperative hepatic artery thrombosis (HAT) and portal vein thrombosis (PVT) and the survival at 90 days.
We collected baseline data of patients which were age, gender, body mass index (BMI), model for end-stage liver disease (MELD) score, haemoglobin level, platelets, neutrophil and lymphocyte counts and international normalised ratio (INR). We also collected intraoperative variables including total intraoperative fluid replacement with crystalloids and/or colloids, requirement of TXA treatment with total dose and total blood product transfusion requirement of packed red blood cells (PRBC), fresh frozen plasma (FFP), platelet, cryoprecipitate, cell saver red blood cells (RBC) and fibrinogen concentrate. Postoperative variables were ICU length of stay, time until extubation, postoperative development of HAT and PVT and the survival at 90 days. We grouped the patients according to intraoperative treatment of TXA, platelet transfusion or combined treatment of TXA and platelets.
Alsabani M.H., Sibai A., Alharbi S.F., Olayan L.H., Samman A.A, & Al Harbi M.K. (2023). Characteristics and Outcomes of Liver Transplantation Recipients after Tranexamic Acid Treatment and Platelet Transfusion: A Retrospective Single-Centre Experience. Medicina, 59(2), 219.
Publication 2023
BLOOD Blood Platelets Blood Transfusion Cells Colloids Combined Modality Therapy End Stage Liver Disease Erythrocytes Fibrinogen Gender Hemoglobin Hepatic Artery Index, Body Mass International Normalized Ratio Lymphocyte Count Neutrophil Patients Plasma, Fresh Frozen Platelet Transfusion Red Blood Cell Transfusion Solutions, Crystalloid Thrombosis Tracheal Extubation Veins, Portal Venous Thrombosis

Top products related to «Platelet Transfusion»

1
Kx 21n by Sysmex
Sourced in Japan, Germany, United States, United Kingdom
The KX-21N is a compact, fully automated hematology analyzer designed for small to medium-sized laboratories. It provides reliable and accurate analysis of common blood cell parameters, including red blood cells, white blood cells, and platelets.
2
Fico lite lm by Atlanta Biologicals
Sourced in United States
The Fico/Lite-LM is a compact and versatile lab equipment designed for a range of applications. It provides reliable and consistent performance in various laboratory settings.
3
Celltracker green cmfda by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, Belgium, Japan, Canada
CellTracker Green CMFDA is a fluorescent dye that can be used to stain live cells. It is designed to passively diffuse into cells and become fluorescently labeled, allowing for the visualization and tracking of cell populations.
4
Aquasonic clear by Parker Laboratories
Sourced in United States
Aquasonic Clear is a transparent ultrasound gel from Parker Laboratories. It is designed for use in diagnostic and therapeutic ultrasound applications.
5
Ethylene diamine tetraacetic acid (edta) by BD
Sourced in United States, United Kingdom, Germany, Brazil, Canada, Japan, Belgium
EDTA is a chemical compound commonly used as an anticoagulant in laboratory settings. Its primary function is to chelate (bind) metal ions, which is essential for various analytical and diagnostic procedures.
6
Spss statistics version 22 by IBM
Sourced in United States, Japan, United Kingdom, Germany, Belgium, Australia, Spain, Switzerland
SPSS Statistics version 22 is a statistical software application developed by IBM. It is designed to analyze and manipulate data, providing users with tools for data management, statistical analysis, and reporting. The software supports a wide range of data types and offers a variety of statistical procedures, enabling users to explore relationships, test hypotheses, and generate insights from their data.
7
Geneprint 24 system by Promega
Sourced in Israel, United States, Canada
The GenePrint 24 System is a forensic DNA profiling kit that amplifies 24 genetic markers for human identification. It provides a reliable and efficient method for generating high-quality DNA profiles from a variety of sample types.
8
Stata version 11 by StataCorp
Sourced in United States, Denmark, United Kingdom
STATA version 11 is a software package for statistical analysis, data management, and graphics. It provides a wide range of statistical tools and functions for researchers, analysts, and professionals in various fields. The core function of STATA version 11 is to perform advanced statistical analysis and modeling on data.
9
Bactec plus aerobic and lytic anaerobic media by BD
The BD Bactec Plus Aerobic and Lytic Anaerobic media are culture media used for the detection and growth of aerobic and anaerobic microorganisms from patient samples. These media are designed to support the growth of a wide range of microorganisms and provide a reliable testing environment for clinical microbiology laboratories.
10
Anti mouse cd4 mab by BioXCell
The Anti-mouse CD4 mAb is a monoclonal antibody that specifically binds to the CD4 receptor on mouse T cells. It is a useful tool for the identification and isolation of mouse CD4+ T cells in flow cytometry and cell sorting applications.

More about "Platelet Transfusion"

Platelet Transfusion, also known as Thrombocyte Transfusion, is the process of transferring platelet-rich blood components from a donor to a recipient.
Platelets, also referred to as Thrombocytes, play a crucial role in blood clotting and wound healing, making platelet transfusions essential for treating conditions like Thrombocytopenia, Cancer, and Bleeding Disorders.
This process involves the collection, processing, and administration of platelet-rich blood products.
Researchers can leverage PubCompare.ai's AI-powered platform to optimize their Platelet Transfusion protocols, locate the latest literature, pre-prints, and patents, and identify the most reproducible and accurate approaches.
Platelet Transfusion procedures may utilize techniques such as Platelet-Rich Plasma (PRP) or Apheresis to extract and concentrate platelets from donor blood.
The transfused platelets can help improve clotting, reduce bleeding, and support the immune system in patients with Platelet deficiencies or disorders.
Considerations surrounding Platelet Transfusion include donor compatibility, storage conditions, and potential risks like Transfusion-Related Acute Lung Injury (TRALI) or Transfusion-Associated Circulatory Overload (TACO).
Researchers can explore the latest advancements in Platelet Transfusion, such as the use of KX-21N, Fico/Lite-LM, CellTracker Green CMFDA, and Aquasonic Clear, to enhance their research and optimize patient outcomes.
Additionally, the use of EDTA, SPSS Statistics version 22, GenePrint 24 System, STATA version 11, and BD Bactec Plus Aerobic and Lytic Anaerobic media may provide valuable insights and tools for Platelet Transfusion research and analysis.
Anti-mouse CD4 mAb can also be utilized in related studies to investigate the immune system's response to Platelet Transfusion.
By leveraging PubCompare.ai's AI-driven platform and the latest advancements in Platelet Transfusion research, scientists and clinicians can enhance their understanding, optimize their protocols, and ultimately improve patient care.